• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全球新冠疫情经历:通过环境评估和血清阳性监测实现创新

The Global COVID-19 Pandemic Experience: Innovation Through Environmental Assessment and Seropositivity Surveillance.

作者信息

Park Robert M

机构信息

National Institute for Occupational Safety and Health, Cincinnati, OH 45230, USA.

出版信息

Int J Environ Res Public Health. 2025 Jul 18;22(7):1145. doi: 10.3390/ijerph22071145.

DOI:10.3390/ijerph22071145
PMID:40724210
Abstract

OBJECTIVES

To confirm a conjecture from year 2020 of the SARS-CoV-2 (COVID-19) pandemic suggesting policy alternatives to substantially reduce mortality burden.

METHODS

Data from a global COVID-19 database comparing different countries on cumulative mortality and vaccination were analyzed in conjunction with surveys of seropositivity. Predictions of final mortality burden under an alternate policy scenario for Japan were calculated and the COVID-19 outcomes for China were assessed.

RESULTS

By 2025, Western countries (US, UK, Brazil and Italy) had cumulative mortality rates in the range of 3339-3548 deaths per million, about 6-fold higher than East Asian and New Zealand 'zero-COVID' countries. Moderate virus suppression in Japan produced the lowest cumulative mortality of the countries analyzed; if earlier policies had been maintained, the predicted cumulative mortality rate by 2025 would be one-tenth that of the US, UK, Brazil and Italy and one-half to one-third that of other zero-COVID countries. For China, transitioning from a zero-COVID policy in 2022-2023, the estimated 2025 cumulative mortality was 1607/million, half that of Western countries.

CONCLUSIONS

To minimize COVID-19 mortality would require: (1) Innovation on systematic sampling of ambient airborne virus exposure to sustain low but non-zero virus levels across entire populations, and (2) seropositivity assessment (instead of mass PCR testing for new cases) for calibrating exposure management, and tracking and protecting high-risk populations.

摘要

目标

证实2020年新冠疫情期间的一个猜想,该猜想提出了大幅减轻死亡负担的政策选择。

方法

结合血清阳性调查,分析了一个全球新冠数据库中不同国家在累计死亡率和疫苗接种方面的数据。计算了日本在另一种政策情景下的最终死亡负担预测,并评估了中国的新冠疫情结果。

结果

到2025年,西方国家(美国、英国、巴西和意大利)的累计死亡率在每百万3339 - 3548例死亡之间,约为东亚和新西兰“动态清零”国家的6倍。日本适度的病毒抑制措施使其在分析的国家中累计死亡率最低;如果维持早期政策,到2025年预测的累计死亡率将是美国、英国、巴西和意大利的十分之一,是其他“动态清零”国家的二分之一到三分之一。对于中国,在2022 - 2023年从“动态清零”政策转变后,预计2025年的累计死亡率为每百万1607例,是西方国家的一半。

结论

为使新冠死亡人数降至最低,需要:(1)创新对环境空气传播病毒暴露的系统采样,以在整个人口中维持低但非零的病毒水平,以及(2)进行血清阳性评估(而非对新病例进行大规模核酸检测)以校准暴露管理,并跟踪和保护高危人群。

相似文献

1
The Global COVID-19 Pandemic Experience: Innovation Through Environmental Assessment and Seropositivity Surveillance.全球新冠疫情经历:通过环境评估和血清阳性监测实现创新
Int J Environ Res Public Health. 2025 Jul 18;22(7):1145. doi: 10.3390/ijerph22071145.
2
Antibody tests for identification of current and past infection with SARS-CoV-2.抗体检测用于鉴定 SARS-CoV-2 的现症感染和既往感染。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.
3
Physical interventions to interrupt or reduce the spread of respiratory viruses.物理干预措施以阻断或减少呼吸道病毒的传播。
Cochrane Database Syst Rev. 2023 Jan 30;1(1):CD006207. doi: 10.1002/14651858.CD006207.pub6.
4
Laboratory-based molecular test alternatives to RT-PCR for the diagnosis of SARS-CoV-2 infection.基于实验室的分子检测替代 RT-PCR 用于 SARS-CoV-2 感染的诊断。
Cochrane Database Syst Rev. 2024 Oct 14;10(10):CD015618. doi: 10.1002/14651858.CD015618.
5
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.用于 SARS-CoV-2 感染诊断的快速、即时抗原检测。
Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3.
6
Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023.1980年至2023年全球、区域和国家儿童常规疫苗接种覆盖率趋势及2030年预测:2023年全球疾病负担研究的系统分析
Lancet. 2025 Jun 24. doi: 10.1016/S0140-6736(25)01037-2.
7
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
8
Effects of city design on transport mode choice and exposure to health risks during and after a crisis: a retrospective observational analysis.危机期间及之后城市设计对交通方式选择和健康风险暴露的影响:一项回顾性观察分析
Lancet Planet Health. 2025 Jun;9(6):e467-e479. doi: 10.1016/S2542-5196(25)00088-9.
9
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
10
The effect of sample site and collection procedure on identification of SARS-CoV-2 infection.样本采集部位和采集程序对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染鉴定的影响。
Cochrane Database Syst Rev. 2024 Dec 16;12(12):CD014780. doi: 10.1002/14651858.CD014780.

本文引用的文献

1
Estimate of COVID-19 Deaths, China, December 2022-February 2023.2022 年 12 月至 2023 年 2 月期间中国 COVID-19 死亡人数的估计。
Emerg Infect Dis. 2023 Oct;29(10):2121-2124. doi: 10.3201/eid2910.230585. Epub 2023 Aug 28.
2
COVID-19 Mortality by Usual Occupation and Industry:46 States and New York City, United States, 2020.2020 年美国 46 个州和纽约市按常见职业和行业划分的 COVID-19 死亡率。
Natl Vital Stat Rep. 2022 Oct;71(6):1-33.
3
SARS-CoV-2 Seroconversion in Response to Infection and Vaccination: a Time Series Local Study in Brazil.
巴西一项时间序列的本地研究:感染和接种疫苗后针对 SARS-CoV-2 的血清转化。
Microbiol Spectr. 2022 Aug 31;10(4):e0102622. doi: 10.1128/spectrum.01026-22. Epub 2022 Jun 30.
4
Time Trend in SARS-CoV-2 Seropositivity, Surveillance Detection- and Infection Fatality Ratio until Spring 2021 in the Tirschenreuth County-Results from a Population-Based Longitudinal Study in Germany.2021 年春季前 SARS-CoV-2 血清阳性率、监测检出率和感染病死率的时间趋势——德国一项基于人群的纵向研究结果。
Viruses. 2022 May 27;14(6):1168. doi: 10.3390/v14061168.
5
COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.俄罗斯圣彼得堡的 COVID-19 疫情:结合基于人群的血清学研究和监测数据。
PLoS One. 2022 Jun 15;17(6):e0266945. doi: 10.1371/journal.pone.0266945. eCollection 2022.
6
Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies - United States, September 2021-February 2022.血清抗体阳性率:美国,2021 年 9 月至 2022 年 2 月。
MMWR Morb Mortal Wkly Rep. 2022 Apr 29;71(17):606-608. doi: 10.15585/mmwr.mm7117e3.
7
Population Immunity and Covid-19 Severity with Omicron Variant in South Africa.南非奥密克戎变异株下的人群免疫力与新冠病毒疾病严重程度。
N Engl J Med. 2022 Apr 7;386(14):1314-1326. doi: 10.1056/NEJMoa2119658. Epub 2022 Feb 23.
8
SARS-CoV-2 Seroprevalence in Germany.德国的 SARS-CoV-2 血清流行率。
Dtsch Arztebl Int. 2021 Dec 3;118(48):824-831. doi: 10.3238/arztebl.m2021.0364.
9
Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK).SARS-CoV-2 疫苗接种前抗体反应的决定因素:一项基于人群的纵向研究(COVIDENCE UK)。
BMC Med. 2022 Feb 22;20(1):87. doi: 10.1186/s12916-022-02286-4.
10
SARS-CoV-2 seroprevalence in Aden, Yemen: a population-based study.也门亚丁的 SARS-CoV-2 血清流行率:一项基于人群的研究。
Int J Infect Dis. 2022 Feb;115:239-244. doi: 10.1016/j.ijid.2021.12.330. Epub 2021 Dec 17.